MetLife Investment Management’s Axcelis ACLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.6M | Buy |
17,235
+188
| +1% | +$16.6K | 0.01% | 1177 |
|
|
2025
Q4 | $1.37M | Sell |
17,047
-1,693
| -9% | -$142K | 0.01% | 1260 |
|
|
2025
Q3 | $1.83M | Buy |
+18,740
| New | +$1.51M | 0.01% | 1130 |
|
|
2025
Q2 | – | Sell |
-19,155
| Closed | -$951K | – | 2736 |
|
|
2025
Q1 | $951K | Sell |
19,155
-730
| -4% | -$46.2K | 0.01% | 1400 |
|
|
2024
Q4 | $1.39M | Buy |
19,885
+1,095
| +6% | +$90.9K | 0.01% | 1253 |
|
|
2024
Q3 | $1.97M | Hold |
18,790
| – | – | 0.01% | 1023 |
|
|
2024
Q2 | $2.67M | Buy |
18,790
+2,038
| +12% | +$235K | 0.02% | 843 |
|
|
2024
Q1 | $1.87M | Sell |
16,752
-304
| -2% | -$36.2K | 0.01% | 978 |
|
|
2023
Q4 | $2.21M | Hold |
17,056
| – | – | 0.02% | 912 |
|
|
2023
Q3 | $2.78M | Sell |
17,056
-220
| -1% | -$38.7K | 0.02% | 748 |
|
|
2023
Q2 | $3.17M | Buy |
17,276
+115
| +0.7% | +$16.6K | 0.02% | 724 |
|
|
2023
Q1 | $2.29M | Buy |
17,161
+83
| +0.5% | +$9.75K | 0.02% | 867 |
|
|
2022
Q4 | $1.36M | Sell |
17,078
-562
| -3% | -$39.6K | 0.01% | 1064 |
|
|
2022
Q3 | $1.07M | Hold |
17,640
| – | – | 0.01% | 1151 |
|
|
2022
Q2 | $967K | Hold |
17,640
| – | – | 0.01% | 1224 |
|
|
2022
Q1 | $1.33M | Buy |
17,640
+6,057
| +52% | +$414K | 0.01% | 1175 |
|
|
2021
Q4 | $864K | Hold |
11,583
| – | – | 0.01% | 1191 |
|
|
2021
Q3 | $545K | Sell |
11,583
-2,351
| -17% | -$102K | ﹤0.01% | 1475 |
|
|
2021
Q2 | $563K | Hold |
13,934
| – | – | ﹤0.01% | 1496 |
|
|
2021
Q1 | $573K | Hold |
13,934
| – | – | 0.01% | 1447 |
|
|
2020
Q4 | $406K | Hold |
13,934
| – | – | ﹤0.01% | 1589 |
|
|
2020
Q3 | $307K | Hold |
13,934
| – | – | ﹤0.01% | 1618 |
|
|
2020
Q2 | $388K | Hold |
13,934
| – | – | ﹤0.01% | 1519 |
|
|
2020
Q1 | $255K | Hold |
13,934
| – | – | ﹤0.01% | 1568 |
|
|
2019
Q4 | $336K | Hold |
13,934
| – | – | ﹤0.01% | 1673 |
|
|
2019
Q3 | $238K | Hold |
13,934
| – | – | ﹤0.01% | 1844 |
|
|
2019
Q2 | $210K | Hold |
13,934
| – | – | ﹤0.01% | 2002 |
|
|
2019
Q1 | $280K | Hold |
13,934
| – | – | ﹤0.01% | 1788 |
|
|
2018
Q4 | $248K | Hold |
13,934
| – | – | ﹤0.01% | 1791 |
|
|
2018
Q3 | $274K | Hold |
13,934
| – | – | ﹤0.01% | 1910 |
|
|
2018
Q2 | $276K | Buy |
+13,934
| New | +$306K | ﹤0.01% | 1751 |
|
|
2018
Q1 | – | Sell |
-13,934
| Closed | -$400K | – | 2182 |
|
|
2017
Q4 | $400K | Buy |
+13,934
| New | +$438K | ﹤0.01% | 1530 |
|
Other funds holding ACLS
VPM
RP
VCM
MetLife Investment Management's ACLS Position: Q1 2026 in Review
MetLife Investment Management increased its Axcelis (ACLS) stake by 1.1% in Q1 2026, buying an estimated $16.6K and bringing the position to 17,235 shares worth $1.6M. The position accounts for 0.01% of the portfolio, ranked #1177.
MetLife Investment Management first reported a position in ACLS in Q4 2017 and has held it in 32 quarters since. The position peaked at $3.17M in Q2 2023. 377 funds tracked by Wall St. Rank hold ACLS as of Q1 2026.
- MetLife Investment Management held 17,235 shares of Axcelis worth $1.6M as of Q1 2026.
- MetLife Investment Management bought 188 Axcelis shares in Q1 2026, an estimated $16.6K.
- Axcelis made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1177 holding.
- MetLife Investment Management first reported a position in Axcelis in Q4 2017 and has held it in 32 quarters since.
- MetLife Investment Management's Axcelis position peaked at $3.17M in Q2 2023.
- 377 funds tracked by Wall St. Rank held Axcelis as of Q1 2026.
Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.